Karyopharm Therapeutics (KPTI) Reports In-Line Q3 EPS

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.65), in-line with the analyst estimate of ($0.65). Revenue for the quarter came in at $0 , versus $30 thousand reported last year.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Astrana Health (ASTH) Mentioned as short at Glass House
• Piper Sandler Reiterates Overweight Rating on Block Inc. (XYZ)